New approach aims to tame immune storms in Half-Matched stem cell transplants

NCT ID NCT06828796

Recruiting now Disease control Sponsor: Northside Hospital, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times

Summary

This study tests whether giving the immune-suppressing drug tacrolimus earlier than usual can lower the risk of cytokine release syndrome (a severe immune reaction) in people receiving a half-matched stem cell transplant for blood cancer. About 20 adults will take part, and researchers will monitor side effects and safety during the first days after transplant. The goal is to make this type of transplant safer and more manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASE AND DISORDERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Northside Hospital
RECRUITING

Atlanta, Georgia, 30342, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HEMATOLOGIC DISEASE AND DISORDERS HEMATOPOIETIC CELL TRANSPLANT